Ubs Asset Management Americas Inc Celldex Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 131,296 shares of CLDX stock, worth $2.62 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
131,296
Previous 116,317
12.88%
Holding current value
$2.62 Million
Previous $2.94 Million
18.92%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CLDX
# of Institutions
188Shares Held
69.3MCall Options Held
220KPut Options Held
310K-
Wellington Management Group LLP Boston, MA8.35MShares$167 Million0.03% of portfolio
-
Kynam Capital Management, LP Princeton, NJ6.5MShares$130 Million9.94% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$93.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.9MShares$77.8 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$74.9 Million1.45% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $933M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...